Top Ten most popular articles on Pharmafile.com this week
pharmafile | July 17, 2020 | News story | Medical Communications | top 10
The news this week as usual centres on treatments and vaccines for COVID-19, with Russia claiming it is the first country to complete a vaccine trial on humans and the first vaccine being used in clinical trials in the US, from Moderna, is set to begin final testing while Gilead’s remdesivir reduced the risk of death in 62% of severe virus patients.
Also in the news, the Trump administration has ordered hospitals to stop sending coronavirus patient data to the Centers for Disease Control and Prevention (CDC) and instead to a central database in Washington, DC, while 20 biopharma firms have come together to launch the AMR Action Fund.
1. Russia claims it has completed the first human trial for COVID-19 vaccine
Russia has become the first country to complete a COVID-19 vaccine trial on humans, according to the Russian News Agency.
2. Trump administration orders hospitals to stop sending COVID-19 data to the CDC
The Trump administration has ordered hospitals to stop sending coronavirus patient data to the Centers for Disease Control and Prevention (CDC) and instead to a central database in Washington, DC.
Itolizumab, a drug currently being developed by biotech firm Equillium for autoimmune and inflammatory disorders, “significantly reduced mortality” in hospitalised COVID-19 patients in an India-based clinical trial, it has emerged.
4. Remdesivir cuts death risk by 62% in coronavirus patients, new study shows
Gilead’s remdesivir reduced the risk of death in 62% of severe COVID-19 patients, according to a new study.
5. Moderna’s COVID-19 vaccine candidate set for final testing in the US
The first COVID-19 vaccine being used in clinical trials in the US is set to begin final testing.
6. Arthritis drug reduces COVID-19 deaths for patients on ventilators
The rheumatoid arthritis drug tocilizumab reduces death rates in coronavirus patients on ventilation, according to new studies.
7. Scientists warn of brain damage linked to COVID-19
COVID-19 could lead to a wave of brain damage in people who were infected with the virus.
Over 20 biopharma firms have come together to launch the AMR Action Fund, an initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), with a goal to deliver between two and four new antibiotic therapies by 2030 in a bid to tackle the growing threat of antibiotic resistance (AMR).
9. UK lockdown caused infection ‘R’ rate to drop as low as 0.57, according to a new study
A new study showed that the coronavirus infection rate hit its lowest point one month before lockdown restrictions were lifted.
10. Pfizer and BioNTech’s COVID-19 vaccines to have their development fast tracked by the FDA
The FDA has granted Pfizer and BioNTech’s COVID-19 vaccine candidates Fast Track status to speed up their development and review.
Conor Kavanagh
Related Content
Pharmafile.com’s top 10 news stories of the week
Among our ten most-read stories this week: NICE has announced that more patients are eligible …
Pharmafile.com’s top 10 news stories of the week
In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer …
Top Ten most popular articles on Pharmafile.com this week
With just around three weeks until the end of a long year, rapidly emerging news …
